A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral Leishmaniasis

Journal of Infectious Diseases

Volumn 191, Issue 12, 2005, Pages 2130-2137

  Tewary, Poonam ^a   Jain, Manju ^a   Sahani, Mayurbhai H ^a   Saxena, Shailendra ^a   Madhubala, Rentala ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; RECOMBINANT ORFF PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; FEMALE; GENE LOCUS; HELPER CELL; IMMUNE RESPONSE; IMMUNITY; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PLASMID; PRIORITY JOURNAL; SPLEEN CELL; VACCINATION; VISCERAL LEISHMANIASIS;

ANIMALS; FEMALE; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 20444402610     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/430348     Document Type: Article

References (46)

1. Carvalho EM, Bacellar O, Barrai A, Badaro R, Johnson WD Jr. Antigen specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Investig 1989; 83:860-4.
2. Carvalho EM. Cell mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun 1981; 33:498-500.
3. Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986; 154:1003-11.
4. Southgate BA. Studies in the epidemiology of East African leishmaniasis. 5. Leishmania adleri and natural immunity. J Trop Med Hyg 1967; 70:33-6.
5. Handman E. Leishmania vaccines: old and new. Parasitol Today 1997; 13:236-8.
6. Gurunathan S, Sacks DL, Brown DR, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997; 186:1137-47.
7. Sjolanader A, Baldwin TM, Curtis JM, Mandman E. Induction of a Th1 response and simultaneous lack of activation of a Th2 response is required for generation of immunity to leishmaniasis. J Immunol 1998; 160:3949-57.
8. + T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69:681-6.
9. Brooks JV, Frank AA, Keen MA, Bellisle JT, Orme IM. Boosting vaccine for tuberculosis. Infect Immun 2001; 69:2714-7.
10. + cytotoxic T lymphocyte population. Int Immunol 2002; 14:31-7.
11. Tanghe A, D'Souza S, Rosseels V, et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun 2001; 69:3041-7.
12. Feng CG, Palendira U, Demangel C, Spratt JM, Malin AS, Britton WJ. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. Infect Immun 2001; 69:4174-6.
13. Takeda A, Igarashi H, Nakamura H, et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J Virol 2003; 77:9710-5.
14. Takeda A, Igarashi H, Nakamura H. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol 2001; 75:11891-6.
15. Robinson HL, Montefiori DC, Johnson RP, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999; 5:526-34.
16. Gilbert SC, Schneider J, Hannan CM, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunization regimes. Vaccine 2002; 20:1039-45.
17. Schneider J, Langermans JA, Gilbert SC, et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 2001; 19:4595-602.
18. Fensterle J, Grode L, Hess J, Kaufmann SH. Effective DNA vaccination against listeriosis by prime/boost inoculation with the gene gun. J Immunol 1999; 163:4510-8.
19. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
20. Matsui M, Moriya O, Akatsuka T. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine 2003; 21:1629-39.
21. Meseda CA, Elkins KL, Merchlinsky MJ, Weir JP. Prime-boost immunization with DNA and modified vaccinia virus Ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific-antibody and cytokine responses than DNA vaccine alone. J Infect Dis 2002; 186:1065-73.
22. Pancholi P, Lee DH, Liu Q, et al. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 2001; 33:448-54.
23. Gonzalo RM, del Real G, Rodriguez JR, et al. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 2002; 20:1226-31.
24. Lange UG, Mastroeni P, Blackwell JM, Stober CB. DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun 2004; 72:4924-8.
25. Ghosh A, Madhubala R, Myler PJ, Stuart KD. Leishmania donovani: characterization and expression of ORFF, a gene amplified from the LD1 locus. Exp Parasitol 1999; 93:225-30.
26. Myler PJ, Venkataraman GM, Lodes MJ, Stuart KD. A frequently amplified region in Leishmania contains a gene that is conserved in prokaryotes and eukaryotes. Gene 1994; 148:187-93.
27. Tripp CA, Wisdom WA, Myler PJ, Stuart KD. A multicopy, extra-chromosomal DNA in Leishmania infantum contains two inverted repeats of the 27.5 kb LD1 sequence and encodes numerous transcripts. Mol Biochem Parasitol 1992; 55:39-50.
28. Raj VS, Ghosh A, Dole VS, Madhubala R. Serodiagnosis of leishmaniasis with recombinant ORFF antigen. Am J Trop Med Hyg 1999; 61: 482-7.
29. Dole VS, Raj VS, Ghosh A, Madhubala R, Myler PJ, Stuart KD. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine 2000; 19:423-30.
30. Sukumaran H, Tewary P, Saxena S, Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 2003; 21:1292-9.
31. Skinner MA, Buddle BM, Wedlock DN. A DNA prime-Mycobacterium bovis BCG boost vaccination strategy for cattle induces protection against bovine tuberculosis. Infect Immun 2003; 71:4901-7.
32. Miyahira Y, Garcia-Sastre A, Rodriguez D, et al. Recombinant viruses expressing a human malaria antigen elicit protective immune CD8+ T cell responses in mice. Proc Natl Acad Sci USA 1998; 95:3954-9.
33. Sedegah M, Jones TR, Kaur M, et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998; 95:7648-53.
34. Li S, Rodrigues M, Rodriguez D, et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 1993; 90:5214-8.
35. Proudfoot L, Nikolaev AV, Feng GJ, et al. Regulation of the expression of nitric oxide synthase and leishmanicidal activity by glycoconjugates of Leishmania lipophosphoglycan in murine macrophages. Proc Natl Acad Sci USA 1996; 93:10984-9.
36. Walker PS, Scharton-Kersten T, Krieg AM, et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-gamma dependent mechanisms. Proc Natl Acad Sci USA 1999; 96:6970-5.
37. Stobie L, Gurunathan M, Prussin C, et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci USA 2000; 97:8427-32.
38. Sypek JP, Chung CL, Mayor SEH, et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993; 177:1797-802.
39. Green SJ, Nacy CA, Meltzer MS. Cytokine-induced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens. J Leukoc Biol 1991; 50:93-103.
40. Carvalho LH, Sano G, Hafalla JC, Morrot A, Curotto de Lafaille MA, Zavala F. IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. Nat Med 2002; 8: 166-70.
41. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21:163-5.
42. Busch DH, Pamer EG. T cell affinity maturation by selective expansion during infection. J Exp Med 1999; 189:701-10.
43. + T cell responses in vivo and in vitro. Proc Natl Acad Sci USA 1999; 96:9781-6.
44. Iborra S, Soto M, Carrión J, et al. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infect Immun 2003; 71:6562-72.
45. Rafati S, Salmanian AH, Taheri T, Vafa M, Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 2001; 19:3369-75.
46. Davis HL, Weeranta R, Waldshmidt TJ, Tygrett L, Schorr J, Krieg M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998; 160:870-6.